Blueberry Therapeutics is a drug discovery and development company that focuses on modern drug delivery using nanopolymer technology. The company specializes in dermatology and nanomedicine, developing innovative therapies for common dermatological disorders.

Blueberry Therapeutics

Blueberry Therapeutics Ltd. is a modern drug discovery and development company which puts people first whether patients, employees, investors or partners. We have created an open, imaginative and fun team environment with a very serious objective: to create new, safer and more effective medicines to treat human disease and make patients feel better.

Blueberry focuses on the research and development of treatments for skin diseases. We do this by employing state of the art preclinical research technologies to generate potent selective and safe molecules (peptides, antibodies, small molecules) for clinical development into new effective treatments to benefit patients. By focusing on well validated drug targets and ensuring our candidate molecules have a very low toxicity liability we believe we can mitigate or even avoid two of the major reasons for drug failures in the clinic.

In the clinic, Blueberry uses smart, agile, clinical designs to deliver high quality trials more rapidly and with reduced development costs. 

Blueberry will rapidly progress new therapies to clinical proof-of-concepts and beyond with appropriate, effective and safe doses with full regulatory and ethical approval.

We have programs addressing Onychomycosis,  Tinea Pedis, Acne and Atopic Dermatitis.

SBRI Healthcare

Incline Equity Partners

Connecticut Skin Institute

Medical Incubator Japan

China Medical Venture Investment (HK) Limited

Catapult Ventures

GM&C Life Sciences Fund

NPIF Maven Equity Finance

Blueberry Therapeutics Ltd

Lovely to be invited back to Staffordshire University’s Careers event last Tuesday. A delight to speak to the students and share careers advice and as always, talk about science! 
#studentengagement #careersfair #science #biosciences

Delighted to be shortlisted for the Bionow awards for Company of the Year, a ‘by invitation only’ category. Thanks to the Bionow judges for shortlisting us after an incredible year, and congratulations to our fellow finalists! https://lnkd.in/e5ZMR-JZ

Blueberry Executives, John Ridden (CEO) and Mark Hollingworth (CFO), are in San Francisco this coming week to meet with industry leaders and investors at the #DermatologySummit (tomorrow, Sunday 7th) and @JPMorgan Healthcare Conference (8th to 11th). Be sure to connect with us if you are attending – we are keen to share our innovative approaches in dermatology and discuss investment and collaborative opportunities.

#BlueberryTherapeutics #Dermatology #DermatologySummit #JPMHC42

Today we are pleased to announce that BB2603, our novel topical terbinafine antifungal product, met primary and secondary endpoints in a Phase 2b trial (BBTAF202) in 111 patients with onychomycosis.

BB2603 was superior to placebo (vehicle), with a high level of statistical significance. These antifungal effects were achieved alongside an excellent safety profile.

You can learn more here: https://lnkd.in/esGvneQh

#dermatology #clinicaldata #drugdevelopment

We’d like to extend a warm welcome to our new Laboratory Technician, Megan Dawson. Megan joins us with a Masters in Medical Microbiology from The University of Manchester, having gained lots of relevant skills in an associate practitioner role at Alder Hey Children’s Hospital. In her spare time, Megan’s interests include attending festivals and gigs, and reading (she is a huge Harry Potter fan). Welcome to Blueberry, Megan!

Metric
Company Name	Blueberry Therapeutics
Symbol
MSH ID	COM:BLUEBERRYTHERAPEUTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Pharmaceuticals
Country	UK
Stage
Employee Count	5
Website	blueberrytherapeutics.com
LinkedIn	blueberry-therapeutics-ltd
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BLUE

COM:BLUEBERRYTHERAPEUTICS

Blueberry Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue